Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2466

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study ; volume:22 ; number:1 ; day:30 ; month:11 ; year:2022 ; pages:1-9 ; date:12.2022
BMC pulmonary medicine ; 22, Heft 1 (30.11.2022), 1-9, 12.2022

Creator: Nio, Yuta
Ishida, Hiroo
Matsumoto, Natsumi
Kusumoto, Sojiro
Kubota, Yutaro
Tsunoda, Takuya
Sasaki, Yasutsuna
Fujita, Ken-ichi

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12890-022-02249-8

URN: urn:nbn:de:101:1-2023021209464221607713

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nio, Yuta
Ishida, Hiroo
Matsumoto, Natsumi
Kusumoto, Sojiro
Kubota, Yutaro
Tsunoda, Takuya
Sasaki, Yasutsuna
Fujita, Ken-ichi
SpringerLink (Online service)

Other Objects (12)

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer

Related objects

Reset password